OncoMatch/Clinical Trials/NCT06536868

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Is NCT06536868 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Etoposide for extensive-stage small-cell lung cancer.

Phase 2RecruitingSecond Hospital of Shanxi Medical UniversityNCT06536868Data as of May 2026

Treatment: Tislelizumab · Etoposide · Carboplatin or Cisplatin — This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Required: Stage IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: anti-pd-1/pd-l1 therapy

Lab requirements

Blood counts

Good function of vital organs

Kidney function

Good function of vital organs

Liver function

Good function of vital organs

Cardiac function

Good function of vital organs

Good function of vital organs

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify